403 related articles for article (PubMed ID: 36658548)
1. Voluntary risk mitigation behaviour can reduce impact of SARS-CoV-2: a real-time modelling study of the January 2022 Omicron wave in England.
Brooks-Pollock E; Northstone K; Pellis L; Scarabel F; Thomas A; Nixon E; Matthews DA; Bowyer V; Garcia MP; Steves CJ; Timpson NJ; Danon L
BMC Med; 2023 Jan; 21(1):25. PubMed ID: 36658548
[TBL] [Abstract][Full Text] [Related]
2. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
[TBL] [Abstract][Full Text] [Related]
3. Lives saved by public health restrictions over the Victorian COVID-19 Delta variant epidemic wave, Aug-Nov 2021.
Delport D; Sacks-Davis R; Abeysuriya RG; Hellard M; Scott N
Epidemics; 2023 Sep; 44():100702. PubMed ID: 37327657
[TBL] [Abstract][Full Text] [Related]
4. Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study.
Davies NG; Barnard RC; Jarvis CI; Russell TW; Semple MG; Jit M; Edmunds WJ; ;
Lancet Infect Dis; 2021 Apr; 21(4):482-492. PubMed ID: 33357518
[TBL] [Abstract][Full Text] [Related]
5. Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand.
Vattiatio G; Lustig A; Maclaren OJ; Plank MJ
Epidemics; 2022 Dec; 41():100657. PubMed ID: 36427472
[TBL] [Abstract][Full Text] [Related]
6. Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study.
Hippisley-Cox J; Khunti K; Sheikh A; Nguyen-Van-Tam JS; Coupland CAC
BMJ; 2023 Jun; 381():e072976. PubMed ID: 37343968
[TBL] [Abstract][Full Text] [Related]
7. Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era.
Barnard RC; Davies NG; ; Jit M; Edmunds WJ
Nat Commun; 2022 Aug; 13(1):4879. PubMed ID: 35986002
[TBL] [Abstract][Full Text] [Related]
8. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
9. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
[TBL] [Abstract][Full Text] [Related]
10. How has the emergence of the Omicron SARS-CoV-2 variant of concern influenced worry, perceived risk and behaviour in the UK? A series of cross-sectional surveys.
Smith LE; Potts HW; Amlôt R; Fear NT; Michie S; Rubin GJ
BMJ Open; 2022 Aug; 12(8):e061203. PubMed ID: 36038165
[TBL] [Abstract][Full Text] [Related]
11. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
COVID-19 Cumulative Infection Collaborators
Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
Krutikov M; Stirrup O; Nacer-Laidi H; Azmi B; Fuller C; Tut G; Palmer T; Shrotri M; Irwin-Singer A; Baynton V; Hayward A; Moss P; Copas A; Shallcross L;
Lancet Healthy Longev; 2022 May; 3(5):e347-e355. PubMed ID: 35531432
[TBL] [Abstract][Full Text] [Related]
14. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
[TBL] [Abstract][Full Text] [Related]
15. Vaccine Effectiveness Against the SARS-CoV-2 B.1.1.529 Omicron Variant in Solid Organ and Islet Transplant Recipients in England: A National Retrospective Cohort Study.
Callaghan CJ; Curtis RMK; Mumford L; Whitaker H; Pettigrew G; Gardiner D; Marson L; Thorburn D; White S; Parmar J; Ushiro-Lumb I; Manas D; Ravanan R;
Transplantation; 2023 May; 107(5):1124-1135. PubMed ID: 36727724
[TBL] [Abstract][Full Text] [Related]
16. An assessment of the vaccination of school-aged children in England against SARS-CoV-2.
Keeling MJ; Moore SE
BMC Med; 2022 May; 20(1):196. PubMed ID: 35581585
[TBL] [Abstract][Full Text] [Related]
17. Impact of interventions to reduce nosocomial transmission of SARS-CoV-2 in English NHS Trusts: a computational modelling study.
Evans S; Stimson J; Pople D; White PJ; Wilcox MH; Robotham JV
BMC Infect Dis; 2024 May; 24(1):475. PubMed ID: 38714946
[TBL] [Abstract][Full Text] [Related]
18. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
19. Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model.
Pople D; Monk EJM; Evans S; Foulkes S; Islam J; Wellington E; Atti A; Hope R; Robotham J; Hopkins S; Brown CS; Hall VJ;
BMJ; 2022 Jul; 378():e070379. PubMed ID: 35858689
[TBL] [Abstract][Full Text] [Related]
20. Non-pharmacological measures implemented in the setting of long-term care facilities to prevent SARS-CoV-2 infections and their consequences: a rapid review.
Stratil JM; Biallas RL; Burns J; Arnold L; Geffert K; Kunzler AM; Monsef I; Stadelmaier J; Wabnitz K; Litwin T; Kreutz C; Boger AH; Lindner S; Verboom B; Voss S; Movsisyan A
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD015085. PubMed ID: 34523727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
